GILD vs. BMY
Compare and contrast key facts about Gilead Sciences, Inc. (GILD) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: GILD or BMY.
Key characteristics
GILD | BMY | |
---|---|---|
YTD Return | -18.69% | -12.36% |
1Y Return | -16.77% | -33.00% |
3Y Return (Ann) | 5.15% | -7.92% |
5Y Return (Ann) | 4.11% | 2.08% |
10Y Return (Ann) | 1.32% | 1.76% |
Sharpe Ratio | -0.81 | -1.46 |
Daily Std Dev | 21.60% | 21.42% |
Max Drawdown | -70.83% | -70.62% |
Current Drawdown | -27.76% | -42.60% |
Fundamentals
GILD | BMY | |
---|---|---|
Market Cap | $81.58B | $90.90B |
EPS | $4.50 | -$3.10 |
PE Ratio | 14.54 | 12.68 |
PEG Ratio | 0.42 | 2.24 |
Revenue (TTM) | $27.45B | $45.53B |
Gross Profit (TTM) | $21.62B | $36.38B |
EBITDA (TTM) | $12.82B | $18.20B |
Correlation
The correlation between GILD and BMY is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
GILD vs. BMY - Performance Comparison
In the year-to-date period, GILD achieves a -18.69% return, which is significantly lower than BMY's -12.36% return. Over the past 10 years, GILD has underperformed BMY with an annualized return of 1.32%, while BMY has yielded a comparatively higher 1.76% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
GILD vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Gilead Sciences, Inc. (GILD) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
GILD vs. BMY - Dividend Comparison
GILD's dividend yield for the trailing twelve months is around 4.63%, less than BMY's 5.33% yield.
TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences, Inc. | 4.63% | 3.70% | 3.40% | 3.91% | 4.67% | 3.88% | 3.65% | 2.90% | 2.57% | 1.27% | 0.00% | 0.00% |
Bristol-Myers Squibb Company | 5.33% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% | 3.31% |
Drawdowns
GILD vs. BMY - Drawdown Comparison
The maximum GILD drawdown since its inception was -70.83%, roughly equal to the maximum BMY drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for GILD and BMY. For additional features, visit the drawdowns tool.
Volatility
GILD vs. BMY - Volatility Comparison
The current volatility for Gilead Sciences, Inc. (GILD) is 4.94%, while Bristol-Myers Squibb Company (BMY) has a volatility of 9.68%. This indicates that GILD experiences smaller price fluctuations and is considered to be less risky than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
GILD vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Gilead Sciences, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities